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PROPHYLAXIS OF OPPORTUNISTIC
INFECTIONS
QUESTION: In your clinic do you stop pro-
phylaxis for PCP when patients go up above
a CD4 count of 200?
DR. CURRIER: Not routinely. I enroll the pa-
tients in the ongoing study, if they are inter-
ested. Sometimes patients stop prophylaxis on
their own and do not tell me that they have de-
cided to discontinue it. But I have not been rou-
tinely recommending discontinuation without
more data.
MR. FROST (MODERATOR): What about
mycobacterium avium complex (MAC)?
DR. CURRIER: It is [stopped]. But I do not
go around discontinuing it as a matter of rou-
tine.
MR. FROST (MODERATOR): Dr. Rubin, do
you discontinue MAC therapy or MAC pro-
phylaxis?
DR. RUBIN: Yes. However, I am not doing a
study, so I understand why you [Currier] do
not. But I believe that CD4 count is probably
the biggest risk for acquiring MAC. As a result,
once my patients' CD4 counts bound over 100,
I will routinely stop it. For those patients who
do not respond to the HAART regimens, I will
maintain it. Fortunately, it is a relatively small
percentage. I will never stop Pneumocystic
carinii pneumonia (PCP) prophylaxis unless
there is some . . .
MR. FROST (MODERATOR): Is there a pos-
itive blood culture that you might use or a neg-
ative blood culture to guide you, or do you just
look at the CD4 counts?
DR. RUBIN: If someone has what might be an
incubated case of a disseminated MAC, that is
a different issue. But that is a clinical judgment,
and that has to be individualized. In terms of
just as a way to approach it, it is one of the pro-
phylaxes that I feel comfortable stopping.
'Director, Clinical Research and Information, American Foundation for AIDS Research, New York, New York.
2St. Vincent's Hospital, New York, New York.
3Research Director, Community Research Initiative of New England, Brookline, MA.
4Assistant Professor of Clinical Medicine, University of Southern California, Los Angeles, CA.
5Associate Professor of Clinical Medicine, Department of Medicine, Columbia Presbyterian, New York, New York.
6Director, Division of Infectious Diseases, Harlem Hospital Center, New York, New York.
7Assistant Professor, Stanford University, Director, AIDS Research Center, Palo Alto VA Medical System, California.
8Assistant Director of Education, AIDS Foundation Houston.
'Assistant Professor of Medicine, Associate Director, Center for Special Studies, The New York Hospital-Cornell
University Medical College, New York, New York.
10Columbia University, New York, New York.
nClinical Instructor of Medicine, Cornell University Medical College, Director AIDS Center, New York Hospital,Queens, New York.
12Newark Community Health Center, New Jersey.
"Associate Professor of Medicine, Director, AIDS Outpatient Clinic, University of Alabama, Birmingham.
557
558 FROST ET AL.
DR. EL-SADR: There are two studies that I
am going to refer to answer these questions.
One is a study that Dr. Currier is leading, the
ACTG. The other study I am leading, the
CPCRA. There are many sites in New York City
that are currently trying to enroll patients for
these studies.
I am concerned that a lot of people are doing
simply what they feel comfortable doing. How
much are we going to be able to learn from these
observational data? Obviously, a selection bias
enters in with who we decide to stop and who
we decide to continue on prophylaxis. Proba-
bly the only way we are going to learn defini-
tively as much as possible is to enroll these pa-
tients in studies so in the end we can rec-
ommend something that is safe and effective.
MR. FROST (MODERATOR): What about
CMV disease? Is there consensus around that?
How many of you use prophylaxis with oral
DHPG at less than 50 CD4 cells? Dr. Bellman,
do you use it?
DR. BELLMAN: Yes.
MR. FROST (MODERATOR): Prophylacti-
cally, at a CD4 count of less than 50?
DR. BELLMAN: Not as a standing recom-
mendation, but certainly in selected patients,
and certainly in patients who have positive cy-
tomegalovirus polymerase chain reaction re-
sults, which I check every couple of months in
patients who have less than 50 CD4 cells.
MR. FROST (MODERATOR): What if their
T-cells go above 50 as a result of . . .
DR. BELLMAN: My feeling is that there is a
clinical response to these drugs that is quite ap-
parent in terms of patients who are very im-
mune compromised. Too often they develop a
whole host of major and minor infections. For
patients who have this clinical response, even
if it is not a complete virologie response, and
even if some of that virologie response is lost
over time, the clinical response, the immuno-
logie response that occurs makes me very com-
fortable trying to minimize using medications
other than the antiretrovirals themselves—be-
cause once again, there are drug interactions,
particularly with rifabutin (Mycobutin), al-
though there are alternatives. Of course, it is al-
ways possible to get burned with a patient off
TMP-SMX (Bactrim) or a relapse of CMV.
But to be honest, with a large group of pa-
tients, I would really have to think hard of a
single patient that I regret taking off prophy-
laxis who afterward developed either a recur-




QUESTION: Do you apply the same kind
of intellectual process when dealing with an-
tiretrovirals [as with opportunistic infec-
tions]? If you have a patient whose viral or
CD4 count goes up to 700 to 800, and who has
been on antiretroviral therapy, would you
consider a "drug holiday" from antiretroviral
agents for them?
DR. COHEN: There are two reasons why you
would consider it. Number one is because
somebody comes in the door and says, "You
know, doctor, I need a drug holiday. My CD4s
are up high enough. I would like to take a
break. Is that okay with you?" And to which I
can only say, "If you take a drug holiday and
we monitor and things stay quiet for a while,
and your CD4s are up here, and even if there
is a rebound of virus, well, then in theory, you
are not resistant to any of these agents we
started. We can just restart it [antiviral therapy]
at some future time point." That is one reason
I am comfortable with the idea of drug holiday.
The second reason is that probably most of
the audience is aware that there are a few anec-
dotes from Europe where people with an ex-
tremely good prognosis did take a regimen,
and then stopped. A year later they still had vi-
ral suppression even in lymph node biopsy
samples where once there was replication.
I think we have more to learn about this than
we know. And while I agree, almost every time
we stop therapy, the virus comes back quickly,
there may be some amount of drug or some du-
ration of suppression that allows a patient to
take a safe drug holiday and just have a break
from all these pills.
DR. EL-SADR: Do you stop all of them?
DR. COHEN: If I am going to stop, I stop the
group. I do not believe in the partial suppres-
sion. I am too afraid of resistance to the regimen.
DR. EL-SADR: It is interesting to hear this
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because I have told my patients that if they feel
they are getting tired of the pills they should just
give me a call. I have had patients who did that,
call me and say, "I woke up this morning, and
I am tired of taking these pills." And we talk
about it. I tell them, "Everybody has bad days
and good days, but keep on taking the pills." It
is almost like a support group, because I am con-
vinced it is important to maintain individuals on
antiretroviral therapy if they are doing well, and
to try to support them over moments of doubt
and moments of sort of battle fatigue.
d4T AND ddl IN COMBINATION
MR. FROST (MODERATOR): This appears
to be an interesting question.
QUESTION: Early on, d4T and ddl seemed
like an unfavorable combination because of
the levels of associated peripheral neuropa-
thy. Has that changed or has something else
changed, because I certainly hear a lot of peo-
ple talking about d4T-ddI as a combination,
and I am wondering if our perception of this
combination has changed or if something ac-
tually biologically has changed?
FEMALE SPEAKER: I think one thing that
has changed is that there is some information
to suggest that ddl can be safely given once a
day. That is very attractive to a lot of people.
Also, I think it improves the tolerability if it is
taken at bedtime once a day. At least in the
clinic where I worked, that caused a lot of peo-
ple to gravitate toward that combination. I also
think the idea of 3TC sparing or saving regi-
mens has increased the popularity of the
d4T-ddI combination.
DR. MERRICK: And then there were data
that showed there was no increased incidence
of neuropathy, and that is what made people
feel alright.
MR. FROST (MODERATOR): Maybe not as
much [neuropathy] as what we were afraid of
early on.
DR. DOBKIN: I also wonder if the fact that
we are in an era where we can suppress viral
load for long periods of time has changed the
way the adverse effects of the nucleosides are
seen in our patients as opposed to the
monotherapy era. For instance, how often do
we see AZT-related anemia as compared with
prior to 1995? Same thing with pancreatitis
from ddl, etc. So I think that something may
have changed in terms of how the patients han-
dle the drugs.
DR. BELLMAN: I would like to disagree
somewhat in the sense of one concern that I
have, with respect to drug toxicities in the com-
bination regimens. I am not sure how accurate
my sense is, but it seems that I am seeing an
awful lot of neuropathy with d4T. In fact, when
I go over the risks and benefits of regimens
with patients comparing, let us say, AZT-3TC-
Crixian versus d4T-3TC-Crixian, it is impor-
tant, in my mind, that patients understand that
the kind of toxicity that they may get from d4T
could, indeed, be irreversible.
I am seeing this also in healthier patients—pa-
tients who are maximally suppressed on the reg-
imens who have been doing well for awhile and
have good T-cell counts. Then when you add
d4T and ddl together, or d4T and ddC (which I
am not sure why in a formal way is not consid-
ered the equivalent of d4T and ddl, and easier
to take), I am very concerned about that.
DR. EL-SADR: I just want to mention that the
CPCRA study with acupuncture shows that
there was not a clearer benefit to using
acupuncture in the treatment of peripheral
neuropathy, although we have used it for over
5 years now, and I have seen that it has been
beneficial.
MALE SPEAKER: My sense of it is that peo-
ple are opposed to AZT-ddl because they just
do not like nausea. I think nausea always loses
because nobody likes to experience it. AZT just
tends to have a little more of it, which is why
I think you are hearing more about d4T-ddI
rather than AZT-ddl.
MALE SPEAKER: We have always argued
from a regional aspect how everybody in New
England or Boston seems to tolerate ddl well,
and here patients have more nausea than they
do with AZT. I do not know what the differ-
ence is.
INDIVIDUALIZING THERAPIES
MR. FROST (MODERATOR): Dr. Saag
talked about issues relevant to dosing with
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women, and that there may be some important
discussion involved. This question takes that
issue from a broader perspective.
QUESTION: How much tailoring of doses
do you really do on an individualized basis?
And how do you get at that lacking informa-
tion on bioavailability?
DR. SAAG: The bottom line is you really can-
not. D4T is adjusted based on weight, and ddl
to some degree. That is about it.
MR. FROST (MODERATOR): Do you adjust
the others or not?
DR. SAAG: It is actually an interesting point.
If I am not misquoting, I think Dr. Markowitz
made a comment about the combination
saquinavir-ritonavir, which is that he feels that
a lot of patients are underdosed on the riton-
avir arm, and their regimen really calls for
pushing people up to 600 twice daily. Those
who will tolerate it are probably metabolizing
it more effectively.
DR. COHEN: Sure, it makes perfect sense.
However, we are left with a conundrum of
sorts. On the one hand, we want the drugs
available as soon as possible for obvious rea-
sons, and I think we should always err on that
side. On the other hand, we are dealing with
the consequences, and that is widespread use
of drugs for which we do not have a full data
set. It is going to take another 5 to 7 years for
that to come into being. What we have to be
willing to do is live with the consequences,
which is what has obviously happened.
MR. FROST (MODERATOR): Tell me how
you live with the consequences? Other than
d4T and ddl, which obviously have some dose
recommendations, do you dose adjust for pro-
teases, for example?
DR. COHEN: We dose adjust for protease
combinations and protease in combination
with non-nucleosides. We know there are likely
to be interactions. We have a chart which I sup-
pose most everybody has some version of in
their clinic. It shows the predicted area under
the curve (AUC) changes based on one column
with one set of drugs; the same drugs are listed
the other way. Then we look at their predicted
AUC changes, and we make a best guess.
MR. FROST (MODERATOR): But that is
based, at least in part, on pharmacokinetic data.
We have seen what delavirdine does, for ex-
ample, with protease inhibitors. We also know,
to a degree, what nevirapine does with pro-
tease inhibitors.
I would like to propose this question. If one
patient comes to your clinic who weights 300
pounds, is 6'2", a big person, and another per-
son comes to your clinic who is 120 pounds and
a very small person, are there any differences
in how you dose those two patients? Let us say,
in both cases, you have chosen AZT-3TC-in-
dinavir.
DR. SAAG: Not right now, But I am worried
about it.
MR. FROST (MODERATOR): Would anyone
else on the panel like to comment?
DR. DOBKIN: It is counterintuitive not to ad-




DR. EL-SADR: I think there are other factors,
in addition to weight, that influence drug me-
tabolism. Even more than resistance testing,
therapeutic drug monitoring will probably be
something that we will be doing in the future.
The problem is, right now, most of the compa-
nies claim that they do not know what level of
their drug is the one that is useful in predict-
ing what the best response is. But I think we
are going to have to start making some as-
sumptions because I believe there is a lot of
variability, particularly in protease inhibitor
metabolism, that may relate to more than
weight alone.
MR. FROST (MODERATOR): Dr. Dobkin,
you said something I thought was important—
that it is intuitive to adjust dosage, but we sim-
ply do not know how.
DR. JAY DOBKIN: Yes, I cannot understand
why we are debating spending $800 on tests for
genotyping, which we clearly do not under-
stand how to apply, and not performing high-
performance liquid chromatography (HPLC)
for drug levels, which I could certainly make a
good crack at applying. If somebody is way be-
low the published levels, then I would increase
the dose.
With a drug like Crixian, for instance, we are
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afraid to push the dose because of toxicity. And
yet something that I would not have expected
to work seems to be working. Giving Crixian
twice a day with ritonavir does boost the lev-
els. It looks like it may be a very attractive reg-
imen. I would feel a lot better doing that if I
had drug monitoring to go along with it.
DR. SAAG: It is really a carryover of the dif-
ferences between pédiatrie and adult medicine.
There are not many infectious diseases in pe-
diatrics that you do not dose on a milligram-
per-kilogram basis. There are few diseases out-
side of oncology in adults you do dose on a
milligram-per-kilogram basis. Maybe ampho-
tericin is one of the exceptions. I think that the
reason that we have done that is a tradition
with antimicrobial therapies for bacteria. The
therapeutic window is so enormous that it does
not matter. But here, we are dealing with much
narrower therapeutic windows. In retrospect, I
think we just made some mistakes.
DR. EL-SADR: Somehow, collectively, we
have not made a strong enough point about the
need for us to look at whether there are any
correlations between these levels and outcome.
DR. SAAG: I do not know that there are data
out there. The problem is to measure protease
inhibitors. It is more than HPLC, and it is not
so easy to do. There may be specimens that are
stored. But then you have to track those spec-
imens back to the actual dosing time to be able
to interpret. I think we would have to do it
prospectively.
DR. BELLMAN: There are a lot of drug in-
teractions that can affect the drug levels of pro-
tease inhibitors that are not listed on the pack-
age inserts. For example, to my knowledge,
Tegretol is an inducer for the enzyme that
breaks down Crixian, and there is no mention
of that in the package insert. I found this out
the hard way. One of my patients who was on
Tegretol failed therapy very early on when
Crixian first became available. I think to this
day, it was probably an example of a drug in-
teraction that is underrecognized, and that is
not formally reported.
So I think there needs to be a mechanism,
maybe every an inclusion in the guidelines, be-
cause that would actually be very useful for
people to have a very complete list of drug in-
teractions and suspected drug interactions.
DR. CURRIER: I want to make one more
comment regarding the differences between
men and women and drug metabolism. What
is interesting is that when people have looked,
they have found some differences. Data on
delavirdine presented by Upjohn Pharmacia
revealed that when they looked at trough lev-
els of the drug in men and women, the women
had significantly higher trough levels than
men. It was not of any obvious clinical conse-
quences during the follow-up time, but there
clearly was a difference between men and
women. I think it is something we really have
to continue to try to look at.
DR. SAAG: Two additional comments. One
is that in many phase I studies, including some
of the ones that we are doing, the sponsors
clearly want a very homogenous population,
and you have to do anthropomorphic mea-
surements. We want to make sure they have
the same volume of distribution. That is clear
as you are trying to dose escalate into people
that you want to understand the bioavailabil-
ity of that drug. But that is a problem as then
it puts the results into a box. The second phase
studies are designed for efficacy in a wide va-
riety of people, and therefore, all bets are off.
The second comment is that, yes, we have to
pay attention to blood levels. But, again, the
way AZT was first dosed was based on phar-
macokinetic principles. Now, the dosage has
evolved from every 4 hours to twice a day, and
we are moving to using ddl once a day. Treat-
ment is clearly changing, and it is important to
know that it is getting to a significant level. But
that may not be the whole story.
DRUG ESCALATION
QUESTION: Now that we are talking in an
era of triple-drug therapies [possibly more],
is it reasonable to consider a strategy that
would begin with fewer drugs, but over a rel-
atively short amount of time introduce the
rest of the regimen in an attempt to minimize
toxicities? Is it a reasonable scenario to sug-
gest perhaps two nucleosides, and maybe a
month or 6 weeks later the addition of a pro-
tease?
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DR. COHEN: There is one instance in which
that was done successfully, and that is in the
ritonavir-saquinavir trial. What we did in that
study was to start with just two protease in-
hibitors (ritonavir-saquinavir) and wait 12
weeks. For anybody whose viral load was not
less than 200, we added two nucleosides, often
d4T-3TC. With that strategy of allowing pa-
tients to kind of declare themselves responders
or not, and then adding two nucleosides for the
people who were inadequate responders, we
actually have achieved over 90% suppression
with success 1 year later.
But to my understanding, that is the only ex-
ample of a successful staggered approach. My
sense would be that that would probably be the
best way to do it. Meaning, use a regimen that
is likely to work for most everybody, and then
intensify before you are going to see resistance.
The worst thing you could do would be to give
an AZT-3TC regimen for 8 weeks because we
know 3TC resistance occurs within a month.
We also know that nevirapine and delavirdine
are lost in a month unless full suppression is
achieved before the 2-week period.
And so, I think if you are going to use that
strategy, you have got to use a regimen that is
unlikely to be lost within the period of time that
you are going to use before you decide to in-
tensify.
MR. FROST (MODERATOR): Were heavily
pretreated patients included among those pa-
tients in the trial, Dr. Cohen?
DR. COHEN: Almost all of them had expe-
riences on all the nucleosides before entering
the study, and they all stopped their nucleo-
sides. The study was done at a time when d4T
and 3TC were relatively new, and most of the
patients had added those two agents, which
they had not taken before. It is probably why
it was so effective.
MR. FROST (MODERATOR): How many pa-
tients had to add nucleosides?
DR. COHEN: About 20%.
FEMALE SPEAKER: There is also a Euro-
pean ritonavir study where they started with
ritonavir alone for 3 weeks, and then added the
nucleosides after that time. I think as long as
that period of time is kept relatively short, it
may improve the ability to tolerate the med-
ication. But I would not feel comfortable with
monotherapy using a protease inhibitor like
that for probably more than 4 to 6 weeks.
MR. FROST (MODERATOR): Does every-
body else feel comfortable with that?
MALE SPEAKER: No, I would try to avoid
that if at all possible, except in the specific sit-
uation with saquinavir-Norvir. If you feel you
are giving a really potent regimen, perhaps that
is one thing. But I think if you are starting off
with two nucleosides and protease monother-
apy, I do not think it is worth taking that
chance. Norvir is going to be hard to tolerate
regardless of what drugs a patient is taking it
with, and I am not sure that the toxicity issue
is very different when it is used as monother-
apy or as triple therapy.
MUTATIONS AND TREATMENT
EFFICACY
QUESTION: Is it true that, even with the
30N mutation present that is associated with
nelfinavir, it is possible to utilize a protease
in the future?
MR. FROST (MODERATOR): David Ho, at
the Interscience Conference of Antimicrobial
Agents and Chemotherapy (ICAAC), called
this story folklore. I recall that a side of Dr. Co-
hen's kind of did it in the reverse. It said the
90 mutation was present, and therefore with-
out the 30N mutation there was still resistance.
But if you flip that question, which has been
done out there, we have all probably been some
of it in one form or another.
DR. COHEN: We are now beginning to get
an inkling of at least the clinical correlation of
the data. And that is some data that were pre-
sented, a study at ICAAC, I think Keith Henry's
presentation, looked at patients who were nel-
finavir failures. They were small numbers, a
dozen patients or so. What was there status in
terms of mutations when they had virologie
failure on a nelfinavir-containing regimen?
Probably about three quarters of those patients
had the 30N mutation. Two or three of the pa-
tients did not have a 30N mutation; they had
the 190M mutation, which was interesting.
Again, there was no saquinavir exposure, nel-
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finavir being the only protease inhibitor they
had.
Subsequently, patients went on to a riton-
avir-saquinavir containing regimen. All of
those patients went to undetectable viral loads
in short-term follow-up. So in the presence of
a 30N mutation and nelfinavir exposure, at
least in small numbers of patients short-term
follow-up, they were able to get a virologie re-
sponse with other protease inhibitors.
MR. FROST (MODERATOR): Take me fur-
ther for a second here, Dr. Cohen. First, you put
these patients on dual protease after nelfinavir
failure. Second, they also had two nucleosides
on board. Third, you saw a positive response.
DR. COHEN: Right.
MR. FROST (MODERATOR): Does that val-
idate these data?
DR. COHEN: No, it does not. It simply sug-
gests people were showing early signs of re-
sponse. I think the punchline will be first of all,
it does not always work, but why not? Is there
a way to make this work by switching at low
viral loads, for example? And second, how long
does this have to last for us to feel confident
that it is safe to rely on? I think 16 weeks is too
soon to judge an approach as successful. At
some point, enough time will have passed to
reach a greater certainty. Keith Henry men-
tioned one patient who is now at week 52 and
has less than 20 viral copies on the riton-
avir-saquinavir regimen.
Now, if that one patient is joined by 10 more
patients, at that point should we feel confident
or not? I think that is going to be when we feel
a bit more certain. Right now, though, it is kind
of a hint rather than enough data to rely on.
PROTEASE INHIBITOR THERAPY
QUESTION: How do you reconcile the
much published data from the Merck proto-
col 035 and the ACTG 320 trial with a deci-
sion not to start a protease inhibitor?
DR. CURRIER: I think that the case that you
gave [in the roundtable discussion] as an ex-
ample was somebody who had higher a T-cell
count and a lower viral load. Clearly, for peo-
ple who have a CD4 count of less than 200, and
in ACTG 320 that was the population that was
studied, I always use a protease inhibitor in
their therapy. I would not have any reservation
to use it. Sometimes, given the results of that
study that not everybody who was on the pro-
tease inhibitor an achieved undetectable viral
load, I might even use more than three drugs,
and use four drugs in some of the patients who
have higher viral loads.
In Merck 035, patients had an average CD4
count of about 140 and viral loads of approxi-
mately 40,000.1 would not hesitate to use a pro-
tease inhibitor in somebody with more ad-
vanced disease.
DR. SAAG: I would look at the glass as half
full rather than half empty in that question. In
other words, if we think further about the
Merck 035, first you have a more advanced pa-
tient, heavily AZT experienced for 12 months
on average, but 85% to 90% did well. Second,
it appears that many also received nucleoside
monotherapy, sometimes considered a sort of
cardinal sin, and still had a response. And
third, the same patients could be rescued later,
at least for 2 years.
MR. FROST (MODERATOR): Is that really
what is driving your thinking?
DR. SAAG: That is a lot of what is driving
my thinking. The other aspect though, which I
had trouble reconciling, is the discrepancy of
the results between Merck 035 and ACTG 320.
I expected the data to show in the two-drug
therapy 50 to 60 progressions, and then in the
three-drug, perhaps two regressions, like the
Merck 035. Well, that was not what we saw.
We saw only, and I underscore only, a 50% re-
duction in clinical events, including mortality.
Well, why is that?
The investigators say, "The CD4 count was
a little bit lower still." And maybe adherence
was more of a problem. Maybe the population
was more heterogeneous in terms of the past
nucleoside experience. So there are a lot of
problems interpreting clinical trial data. You
have to know the details of the study, the cri-
teria for admission, and the homogeneity or
heterogeneity of the population, and so on.
But I would take a lot of that data as some
degree of evidence, ironically, in favor of some-
one like our case presentation [see roundtable
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discussion] and going a little bit slower. ACTG
175 was really what I am basing a lot of my
thought on. That is a study using nucleosides
early on for naive patients. We have about half
of our patients now rolling into yet another it-
eration of that study and doing just fine, thank
you. That is also where I am thinking from.
DR. COHEN: One really important point,
though, is that for both of those studies, the pa-
tients were 3TC naive. I think that has been
very critical to their success. They could have
been on ddl in the past. I think many of them
were, and they were still successful. Some peo-
ple have said, "Well, the participation of the
Merck 035, those must have been the most ex-
traordinary people because they did so well,
and why am I not seeing that in my practice or
my clinic?"
And I think the reason that we are not see-
ing that success, and the reason that Steve
Deecks reported 50% of people not being sup-
pressed with protease inhibitors is that they are
not the same patient. These were people who
had an average viral load of 40,000, and had
never been on 3TC. So we have to understand
the population that was studied, and how we
can reliably generalize those results.
The other success story that we have of peo-
ple who are pretreated is the DMP-indinavir
study. Ninety-five percent of those on just
those two drugs are suppressed a year later,
and all of them could have taken all the nucle-
osides they wanted and still had this very suc-
cessful regimen next.
So, again, I think it is the cross-resistance
within a class that is our undoing. And that is
why there is an increasing feeling that we
should use one class at a time because the other
class will be fresh and ready. I actually intend
to go right to left, protease to nucleoside.
I personally am in the dual-protease mode
first, and maybe even triple-protease mode
first, and then going to a nucleoside second. I
am interested, at least, in exploring that be-
cause I personally have a sense that that might
provide a more successful opening move. And
having done ritonavir-saquinavir, that feels
like it is worth exploring. I do not think it al-
ways has to go left to right (nucleoside to pro-
tease). It is just the way we have done it.
POSTEXPOSURE PROPHYLAXIS
QUESTION: I am wondering among the
physicians who may have seen this, or po-
tentially could see this, how many are apply-
ing post-sexual exposure prophylaxis, and in
what circumstance?
DR. RUBIN: I can say I have not used it. I
think it is a bit of a slippery slope.
MR. FROST (MODERATOR): Would you
use it? Let's say I show up in your clinic and
say, "Listen, last night I had a few beers ..."
DR. RUBIN: I would never say never. I think
that there certainly are situations where it may
be appropriate.
MR. FROST (MODERATOR): Could you tell
me what those are?
DR. RUBIN: A discordant couple would be
the obvious situation. I think that in those cases
it would be appropriate. I am saying I have not
been in a situation where I have been asked to
do that.
DR. DOBKIN: If anyone is unhappy about
the U.S. Public Health Service antiretroviral
guidelines, then they should prepare them-
selves, because New York State is about to is-
sue guidelines on postexposure prophylaxis for
sexual exposure. In fact, I have already told
those of us who have AIDS Institute education
programs to get ready to start disseminating
this material when it is ready. But they have
not told us what the guidelines are yet, so we
will have to wait.
DR. VAUGHN: I think in instances of rape
or something similar that we currently do a
poor job of reinforcing prevention of HIV dis-
ease. This came up with one of our commu-
nity forums. One of the patients was going on
about participating in risky sexual activities
again. I think that we really have to do a bet-
ter job educating at every encounter with pa-
tients and the community, as far as prevention
because the toxicity of the medications just
does not make sense to many them. Some
think postexposure prophylaxis is feasible,
in that we can just take the top tail and have
sex the good old ways as in the good old
days.
With rape situations or something like that,
I would apply it. But to possibly encourage post-
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exposure in settings of sexual exposure, I am
not comfortable with that at all.
DR. CURRIER: But I think that the slippery
slope is to declare that if a health-care worker
gets exposed, we will do something, but in
other situations, we will make further judg-
ments. We need to have some sort of consis-
tency. How do you define what is a potentially
unavoidable exposure? I think if somebody has
an exposure that could not be avoided for
whatever reason, without passing a lot of judg-
ment on them, you have to consider what you
might be able to do to prevent them from get-
ting infected.
MR. FROST (MODERATOR): Well, I am go-
ing to be a bit of the devil's advocate here. In
the health-care setting, there is a significant
body of data gathered by the Centers for Dis-
ease Control. There are no data regarding a sex-
ual environment. And clearly, I think, the ex-
posure sexually could be different than the
exposure in a hospital setting or an emergency
room setting. Should that influence our judg-
ment in any way?
DR. SAAG: If the sexual exposure actually is
a much higher risk than the needle stick, per-
haps. I received a call once of someone who
had unprotected anal receptive intercourse
with a known HIV-positive partner. That is a
pretty high risk. I think it would be ridiculous
not to treat in that situation when we are treat-
ing people for needlesticks where the cumula-
tive incidence is less than 1%. And although
there are data now, when we started doing pro-
phylaxis in needle sticks, there were no data.
Therefore, I do not believe not having the data
is a reason not to do it. I think you need to quan-
tify the risk as best we can the same way we
quantify a needle stick, as high, moderate, and
low risk.
DR. EL-SADR: I agree with some of what has
been said. We have to be careful not to have
hard and fast rules. You have to make a judg-
ment. In the right setting, where an assessment
has been made and there is significant risk, I
find it very difficult to withhold the potentially
favorable treatment. But I think we have to be
careful that this is not done, sort of across the
board repeatedly, in individuals who are re-
peating high-risk behaviors. But I think it is
hard in certain settings to say, "No, I will not
give you the benefit of this treatment."
Another issue that was raised as being
neglected in New York City, New York State,
and perhaps elsewhere, is that there are
very few interventions given in relation to
HIV per se for rape victims, either male or
female.
FEMALE SPEAKER: I think it is important
to add to what Dr. Currier said that there are
not data available which indicate that respon-
sible availability of postexposure prophylaxis
will increase nonadherence to using condoms
for intercourse. It may be that people who feel
like if the condom breaks, or they have one
episode, they have a chance of getting treat-
ment—it may increase their compliance with
safer sex. I think we should not make that as-
sumption.
If a patient comes in with a high-risk expo-
sure, I feel it is my obligation to try to prevent
an infection in them. I cannot sit there and be
judgmental about why they were exposed. But
the difficulty is, again, an access because it is
impossible to expect a third-party payer to pay
for medicines for somebody who has been ex-
posed in that situation. A healthcare worker
has protection through the hospital or the
healthcare employer to pay for their medicines.
And in the case of rape, at least in some states,
that it is paid for by the state or by the institu-
tion.
All to say, when there is no means of pay-
ment, that becomes a rate-limiting step. No-
body pays for people's condoms, for the most
part; they are provided in clinics. But the point
is, contraception is generally something that is
considered a personal responsibility that peo-
ple purchase for themselves. With postexpo-
sure prophylaxis in this setting, the cost is go-
ing to be the rate-limiting step. And that, I
think, is going to probably dampen a lot of the
repeat request for medicines.
MALE SPEAKER: Just one small point. I
think one of the things we learned from the nee-
dle stick experience, and I do not know that we
learned a great deal more, is that education has
been very effective at getting people to realize
when they have had a low-risk exposure. I
think that is going to be important to do a lot
566 FROST ET AL.
of educating about postsexual exposure, per-
haps not to the public, but to contact health-
care workers so they can counsel patients if
they have not had an obviously serious expo-
sure. Otherwise, every bathroom across the




QUESTION: What is the risk that innova-
tive therapeutic combinations, which lie out-
side the guidelines, may not be reimbursed
by third-party payers, or third-party payers
may look askance at it?
DR. SAAG: A distinction should be made be-
tween regimens that are sort of outside the
guidelines with respect to initiation of therapy
for treatment-naive patients, and treatments
that are outside the guidelines for patients who
have failed therapy, because actually there are
no really meaningful guidelines for patients
who failed therapy, regardless of what is in the
guidelines. I think that it is important for us as
physicians to take a very proactive approach
toward the issue of third-party payers, and not
treat the guidelines as something objective and
immutable. Otherwise, they will just deny pa-
tients' treatment options when we think some-
thing might be helpful to them.
I believe we need to have an understanding
at this point. It is true that salvage therapies are
indeed experimental, whatever they may be. On
the other hand, salvage therapies are part of the
medical care of the patient. The fact that that
medical care has now gone to an "experimen-
tal" level does not mean that we should not sup-
port the drugs that those patients need, because
there are patients who do respond to salvage
therapies—those that are in the guidelines, and
also those that are outside of the guidelines.
MR. FROST (MODERATOR): Is this a prob-
lem? Does it come up?
DR. VAUGHN: This issue came up when I
initially started using the combination of Norvir
and saquinavir, depending on what type of in-
surance the person had, such as if the person
was on city welfare. There was one particular
individual. His viral load was going way, way
up after it had been initially suppressed. He was
compliant. It took 6 weeks before the pharma-
cist in Trenton would authorize the combina-
tion Norvir-saquinavir. The only reason he fi-
nally received it was that I hammered the
pharmacist, wrote letters, sent reprints from the
Antiretroviral Meeting, and the results of the
study. Finally they approved it.
You have people who are wedded to the
guidelines, and if the request is anything else
outside of them they will not approve it. I have
the benefit of knowing the patient and all the
other medications that he was on, but some-
body in Trenton is just going to decide that
since he had never heard of that combination
before or actually heard that it was contraindi-
cated, the patient could not have the benefit of
these therapies.
DR. EL-SADR: I think that is the area where
sometimes guidelines are tricky, especially in a
field such as HIV care which changes every
minute of every day and at every meeting.
How can guidelines keep up with reasonable
options for our patients? I wish that the guide-
lines had just dealt with the principles of treat-
ment, which I think are solid and probably will
be with us, at least, for a while. I think once
you start adding names of drugs and doses and
so on, it is going to be almost obsolete by the
time it is printed. So by the time these come
out, and the interactions that these have to go
through, they are going to be obsolete. I think
that is the danger. Although the writers were
well-meaning, and wanted the guidelines to
provide broad access, on the other hand, they
already are obsolete and behind the current rec-
ommendations.
MS. LEONARD: Just to supply reality, in
Texas, if you're on the program, you can get
three drugs. You can only get three drugs. So
if you want two proteases or need two protease
inhibitors and two reverse transcriptase in-
hibitors, you can get three out of the four paid
for. That is how the guidelines have been over-
interpreted.
